Myos Rens Technology has entered into an agreement with the College of Veterinary Medicine at Kansas State University to study the impact of Fortetropin on reducing muscle loss in dogs after ligament tear repair surgery. The study continues the company's investment in research regarding the therapeutic potential of Fortetropin across many broad areas of muscle health.

"The rationale for pursuing this study with Kansas State is two-fold," commented Joseph Mannello, Interim chief executive officer of Myos Rens. "One of our goals is to evaluate Fortetropin's potential to improve musculoskeletal health in dogs. A positive result could lay the foundation for the creation of a companion animal (pet) nutrition business focused on musculoskeletal health.  This could have a substantial benefit to Myos Rens since the global animal health market, now at about $35 billion, is projected to reach $44.2 billion by 2020. Positive results from this study would also lead to testing and developing Fortetropin-based products to aid humans recovering from musculoskeletal surgeries. If Fortetropin supplementation in humans can reduce hospital stays or rehabilitation time by even one day, the savings in healthcare costs could be substantial."

Fortetropin is the company's flagship functional food product.  It is the first natural, clinically proven myostatin-reducing ingredient made for human consumption and was recently brought to market in the Qurr muscle health product line. Qurr's Fortetropin acts to build lean muscle mass and improve strength and endurance. Qurr muscle health products can be purchased at Qurr.com.

This veterinary research study is designed to investigate the impact of Fortetropin on reducing muscle atrophy in dogs after TPLO (tibial-plateau-leveling osteotomy) surgery.  TPLO surgery is a common surgery performed in large dogs such as Labrador Retrievers to stabilize the stifle joint after ruptures of the CCL (cranial cruciate ligament), which is analogous to the ACL (anterior cruciate ligament) in humans.  MYOS RENS anticipates the clinical study will be completed and its results announced in the second quarter of 2018.

Dr. Neerav D. Padliya, vice president, research alliances of Myos Rens, said, "We are excited to be working with the College of Veterinary Medicine at Kansas State University, one of the leading veterinary colleges in the U.S., to explore the utility of Fortetropin in animal health for the first time.  Reducing muscle atrophy in dogs following orthopedic surgery is an area of unmet need."

Kenneth R. Harkin, DVM, Diplomate ACVIM (SAIM), and Hodes Professor of Internal Medicine at Kansas State University, said "My colleagues and I are excited about this collaboration with Myos Rens. Rehabilitation after TPLO surgery, essentially increasing the muscle mass that stabilizes the cruciate deficient knee, has been shown to improve mobility and decrease arthritic changes. Fortetropin, by naturally reducing myostatin levels, offers an innovative approach to rehabilitation that is convenient and accessible to all pet owners. We hope this will be the first of many studies that evaluate the potential benefits of Fortetropin in companion animals."

Myos Rens Technology is a Cedar Knolls, NJ-based biotherapeutics and bionutrition company focused on developing products that improve muscle health and performance and brings them to market.